Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PRMT1 | Q99873 | 12/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | INMT | O95050 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24173221 | 0.86 | PRMT1 (0.35) | PRMT1PRMT6 | |
| SCHEMBL24173026 | 0.81 | PRMT1 (0.33) | PRMT1PRMT6 | |
| SCHEMBL31053394 | 0.79 | HCAR2 (0.35) | KDM4EPRMT1KMT2APRMT6GRM5 | |
| SCHEMBL2436166 | 0.77 | ALDH1A1 (0.33) | PRMT1KMT2APRMT6GRM5MEN1 | |
| SCHEMBL21836672 | 0.75 | SLC6A2 (0.39) | KDM4EKMT2AMEN1RAB9ATHRB | |
| SCHEMBL25786562 | 0.73 | PRMT1 (0.35) | PRMT1PRMT6THRBTGFBR1MAPK14 | |
| SCHEMBL24288747 | 0.72 | SLC22A12 (0.38) | KMT2AMEN1MAPK1THRBMAPK14 | |
| SCHEMBL26978255 | 0.71 | KMT2A (0.33) | KDM4EKMT2AMEN1 | |
| SCHEMBL27396595 | 0.71 | MAPK1 (0.33) | KDM4EPRMT1KMT2AMEN1MAPK1 | |
| SCHEMBL16708908 | 0.70 | KMT2A (0.31) | KDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2844658-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | GENENTECH INC (US) | 2019-03-20 | — | — | EP | disclosed |
| US-9212186-B2 | Bicyclic pyrazole LRRK2 small molecule inhibitors | GENENTECH, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| EP-2844658-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2015-03-11 | — | — | EP | disclosed |
| US-20150051201-A1 | BICYCLIC PYRAZOLE LRRK2 SMALL MOLECULE INHIBITORS | GENENTECH, INC. (US) | 2015-02-19 | — | — | US | disclosed |
| WO-2013164323-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051201-A1 | BICYCLIC PYRAZOLE LRRK2 SMALL MOLECULE INHIBITORS | LRRK2, PARK7, PINK1 | KDM4E 3741/4885PRMT1 497/4885KMT2A 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.